REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 37.00
Ask: 39.00
Change: 1.50 (4.11%)
Spread: 2.00 (5.405%)
Open: 37.00
High: 40.50
Low: 36.75
Prev. Close: 36.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

Thu, 14th Dec 2023 20:20

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says it is optimistic about its pipeline, as its focus remains on advancing its SDC-1801 therapy. Notes that it expects to receive full safety data for SDC-1801 in the first half of 2024. Says it intends to begin a phase 2 study, which will be completed by the end of 2024.

----------

Ethernity Networks Ltd - Israel-based supplier of data processing semiconductor technology for networking appliances - Says it has received a request from 5G Innovation Leaders Fund LLC to issue 61.5 million new shares pursuant to its settlement deed. In November, it issued 44.9 million shares. Says that following the issue, it will have completed its obligations. Says the new shares to be admitted will represent 21% of its issued capital.

----------

Ashoka WhiteOak Emerging Markets Trust PLC - investment trust focused on global emerging markets - Says net asset value total return for period from its IPO in May to September 30 was 2.60%, outperforming its MSCI Emerging Markets Net Return Sterling by 1.2%. Notes that its share price is performing at a 2.2% premium to NAV. Notes that its key drivers of growth were Senco Gold, Gokaldas Exports and DBS Group. Chair Martin Shenfield says: "We are delighted to present our initial Interim Report covering the period to 30 September 2023 which included the company's successful listing on the London Stock Exchange, a landmark IPO for the sector considering the significant drought of new listings in recent years. We retain the conviction outlined at the company's IPO that the investment case for emerging markets remains attractive and that the company's bottom-up investment strategy provides a highly differentiated approach to accessing this key investment theme with the objective of generating outperformance over the long term."

----------

Digital 9 Infrastructure PLC - invests in internet infrastructure, such as data centres and subsea fibre - Says it has appointed Charlotte Valeur as its interim chair. Notes that its sale of Verne Global is on track to be completed by the end of the first quarter of 2024. Valeur comments: "We remain committed to completing the sale of Verne Global and expediting the strategic review to further maximise shareholder value".

----------

CleanTech Lithium PLC - Chile-focused lithium exploration and development - Says its open offer closed for acceptances oversubscribed by 13% at GBP586,000. Notes it was required to scale back its valid applications to its maximum allowance of 2.4 million, raising a total of GBP520,000. Says it has raised a total of GBP8.5 million from its open offer and fundraising programme. Chief Executive Aldo Boitano says: "Thank you to all our shareholders who participated in the recent open offer and to those who voted at our general meeting. It is encouraging to see an active investor base and your continued support is much appreciated as we develop sustainable lithium projects in Chile. I am particularly pleased that our open offer was oversubscribed, a clear vote of confidence for the company's plans in 2024."

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
13 Jun 2019 15:49

Sareum Plans To Start Human Trials Of Two Drug Candidates In 2020

(Alliance News) - Sareum Holdings PLC on Thursday said it has been focusing on toxicology studies in its development of drug candidates SDC-1801 and SDC-1802 with a view to CONDUCT human trials in

Read more
3 Jun 2019 17:38

Sareum Notes Sierra Oncology's Positive Preliminary Results Of SRA737

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint

Read more
3 Jun 2019 10:02

Sareum Reports Positive Data From Trials Of SRA737 In Advanced Cancer

LONDON (Alliance News) - Sareum Holdings PLC on Monday said that Sierra Oncology reported positive preliminary clinical data from two in-human studies of SRA737.Shares in the drug company a

Read more
4 Mar 2019 10:58

Sareum Interim Loss Deepens On Costs As Pipeline Continues Progress

LONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC said Monday its interim loss widened as costs rose, but it made progress with its key developmental programmes.For to

Read more
4 Mar 2019 08:26

Sareum's loss widens as development costs expand

(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.

Read more
28 Feb 2019 14:33

Sareum flags potentially significant findings for SRA737

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.

Read more
11 Dec 2018 15:55

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 12 DecemberBlancco Technology GroupBellwayVolution Shopping REIT (re voluntary 13 Asian 14 to

Read more
30 Nov 2018 11:48

Sareum Reports Efficacy Data For Immunotherapy Combination With SRA737

LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the

Read more
26 Oct 2018 09:20

Sareum Holdings Raises GBP850,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug

Read more
26 Oct 2018 08:38

Sareum raises £850,000 to fund cancer inhibitor

(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.

Read more
1 Oct 2018 11:30

Sareum Swings To Annual Loss After Prior Year Profit From Associates

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at

Read more
26 Sep 2018 15:20

Sareum Holdings selects cancer therapy development candidate

(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.

Read more
26 Sep 2018 14:05

Sareum Selects Candidate To Develop Cancer Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain

Read more
11 Sep 2018 13:28

Sareum Holdings Expects To Swing To GBP1.5 Million Annual Loss

LONDON (Alliance News) - Sareum Holdings PLC said Tuesday it expects to report a loss in its annual results as it progresses on its programmes in autoimmune diseases and cancer.The drug it

Read more
10 Sep 2018 11:52

Sareum Picks SDC-1801 For Development As Autoimmune Disease Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.The molecule, SDC-1801, has been formally selected for is a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.